journal article·2015-09-02

MicroRNA Replacing Oncogenic Klf4 and c-Myc for Generating iPS Cells via CationizedPleurotus eryngiiPolysaccharide-based Nanotransfection

Wenwen Deng, Xia Cao, Jingjing Chen, Zhijian Zhang, Qingtong Yu, Yan Wang, Genbao Shao, Jie Zhou, Xiangdong Gao, Jiangnan Yu, Ximing Xu

Publisher page

Abstract

Induced pluripotent stem cells (iPSCs), resulting from the forced expression of cocktails out of transcription factors, such as Oct4, Sox2, Klf4, and c-Myc (OSKM), has shown tremendous potential in regenerative medicine. Although rapid progress has been made recently in the generation of iPSCs, the safety and efficiency remain key issues for further application. In this work, microRNA 302-367 was employed to substitute the oncogenic Klf4 and c-Myc in the OSKM combination as a safer strategy for successful iPSCs generation. The negatively charged plasmid mixture (encoding Oct4, Sox2, miR302-367) and the positively charged cationized Pleurotus eryngii polysaccharide (CPEPS) self-assembled into nanosized particles, named as CPEPS-OS-miR nanoparticles, which were applied to human umbilical cord mesenchymal stem cells for iPSCs generation after characterization of the physicochemical properties. The CPEPS-OS-miR nanoparticles possessed spherical shape, ultrasmall particle size, and positive surface charge. Importantly, the combination of plasmids Oct4, Sox2, and miR302-367 could not only minimize genetic modification but also show a more than 50 times higher reprogramming efficiency (0.044%) than any other single or possible double combinations of these factors (Oct4, Sox2, miR302-367). Altogether, the current study offers a simple, safe, and effective self-assembly approach for generating clinically applicable iPSCs.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Pluripotent Stem Cells Research · Tissue Engineering and Regenerative Medicine · 3D Printing in Biomedical Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, School of Pharmacy, and Center for Drug/Gene Delivery and Tissue Engineering, Jiangsu University, Zhenjiang 212001, People’s Republic of China

Center for Drug/Gene Delivery and Tissue Engineering, and School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang 212001, People’s Republic of China

School of Life Science & Technology, China Pharmaceutical University, Nanjing 210009, People’s Republic of China

Funding

Priority Academic Program Development of Jiangsu Higher Education Institutions · Industry-University-Research Institution Cooperation Jiangsu Province and Zhenjiang City · National Natural Science Foundation of China · Senior Professionals’ Foundation, Jiangsu University · Ministry of Education of the People's Republic of China · Jiangsu Province

References (55)

Show source-provided references
1. 10.1016/j.cell.2006.07.02410.1016/j.cell.2006.07.024 ↗
2. 10.2217/nnm.14.910.2217/nnm.14.9 ↗
3. 10.1126/science.115152610.1126/science.1151526 ↗
4. 10.1038/nbt.150310.1038/nbt.1503 ↗
5. 10.1242/dev.02086710.1242/dev.020867 ↗
6. 10.1038/nature0653410.1038/nature06534 ↗
7. 10.1016/j.actbio.2014.08.01010.1016/j.actbio.2014.08.010 ↗
8. 10.1166/jbn.2014.198610.1166/jbn.2014.1986 ↗
9. 10.1016/j.celrep.2014.09.05510.1016/j.celrep.2014.09.055 ↗
10. 10.1002/art.3878010.1002/art.38780 ↗
11. 10.1016/j.stem.2008.08.00310.1016/j.stem.2008.08.003 ↗
12. 10.1016/j.cell.2007.11.01910.1016/j.cell.2007.11.019 ↗
13. 10.1016/j.febslet.2014.08.03910.1016/j.febslet.2014.08.039 ↗
14. 10.1038/nature0593410.1038/nature05934 ↗
15. 10.1073/pnas.081142610610.1073/pnas.0811426106 ↗
16. 10.1016/j.stem.2009.05.00510.1016/j.stem.2009.05.005 ↗
17. 10.1038/nbt.153510.1038/nbt.1535 ↗
18. 10.1016/j.stem.2011.05.00110.1016/j.stem.2011.05.001 ↗
19. 10.1002/adfm.20120364610.1002/adfm.201203646 ↗
20. 10.1089/scd.2014.015110.1089/scd.2014.0151 ↗
21. 10.1038/nbt137410.1038/nbt1374 ↗
22. 10.1016/j.stem.2007.12.00110.1016/j.stem.2007.12.001 ↗
23. 10.1089/jop.2014.002010.1089/jop.2014.0020 ↗
24. 10.1038/ncb182710.1038/ncb1827 ↗
25. 10.1038/cr.2010.17210.1038/cr.2010.172 ↗
26. 10.1016/j.stem.2009.09.00810.1016/j.stem.2009.09.008 ↗
27. 10.1016/j.actbio.2014.04.02610.1016/j.actbio.2014.04.026 ↗
28. 10.1158/0008-5472.CAN-09-030910.1158/0008-5472.CAN-09-0309 ↗
29. 10.1038/ng.25010.1038/ng.250 ↗
30. 10.1074/jbc.C111.23596010.1074/jbc.C111.235960 ↗
31. 10.1016/j.stem.2011.03.00110.1016/j.stem.2011.03.001 ↗
32. 10.1007/s10616-013-9639-210.1007/s10616-013-9639-2 ↗
33. 10.1016/j.stemcr.2013.07.00210.1016/j.stemcr.2013.07.002 ↗
34. 10.1002/smll.20110155410.1002/smll.201101554 ↗
35. 10.1002/jbm.a.3137210.1002/jbm.a.31372 ↗
36. 10.1021/am504203x10.1021/am504203x ↗
37. 10.1021/am504617910.1021/am5046179 ↗
38. 10.2147/IJN.S2801010.2147/IJN.S28010 ↗
39. 10.1002/ange.20100574010.1002/ange.201005740 ↗
40. 10.1002/anie.20110020210.1002/anie.201100202 ↗
41. Lu L.-L. · Haematologica · 2006 · 91 · 1017
42. 10.1016/j.vaccine.2011.09.02910.1016/j.vaccine.2011.09.029 ↗
43. 10.1016/j.nano.2013.05.00810.1016/j.nano.2013.05.008 ↗
44. 10.1074/jbc.M112.40388110.1074/jbc.M112.403881 ↗
45. Suzuki M. · Biotechnol. Appl. Biochem. · 1995 · 21 · 33510.1111/j.1470-8744.1995.tb00339.x ↗
46. 10.1126/science.116249410.1126/science.1162494 ↗
47. 10.1016/j.biomaterials.2004.07.05010.1016/j.biomaterials.2004.07.050 ↗
48. 10.1021/nl052396o10.1021/nl052396o ↗
49. 10.1021/nl070363y10.1021/nl070363y ↗
50. 10.1021/nn401418n10.1021/nn401418n ↗
51. 10.1002/ange.20130879510.1002/ange.201308795 ↗
52. 10.1016/j.jconrel.2010.07.10910.1016/j.jconrel.2010.07.109 ↗
53. 10.1038/nature0786410.1038/nature07864 ↗
54. 10.2147/IJN.S5383010.2147/IJN.S53830 ↗
55. 10.1038/nprot.2007.41810.1038/nprot.2007.418 ↗